Search Team

Search by Last Name
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
 
 

Life Sciences

full industries list
Life Sciences Image
News
Events
Litigation Blog
Hatch-Waxman

Fish attorneys have served as leading advisors to pioneers in the pharmaceutical, biotechnology, and life sciences fields for more than a century. For three consecutive years, we have been named the top US law firm for life sciences and biotechnology IP work by Managing Intellectual Property magazine. Clients choose Fish because of the technical and scientific expertise of our internationally recognized attorneys.

Large and small companies, along with academic and research institutions, turn to Fish’s team to protect their most valuable innovations. We offer biotechnology and pharmaceutical clients services that include:

  • Patent portfolio planning, strategic advice, opinions, and prosecution
  • Post-grant proceedings at the USPTO
  • Litigation services, including representation in Hatch-Waxman cases
  • FDA expertise
  • Counsel on licensing and other transactions

We have a rapidly expanding practice representing branded pharmaceutical companies in Hatch-Waxman litigation. Biotechnology and pharmaceutical companies trust Fish’s litigation team to handle these complicated, high-stakes cases because we are the world’s most experienced patent litigators.

Examples of our biotechnology and pharmaceutical work include:

  • Representing dozens of biotechnology and pharmaceutical clients in patent infringement litigation
  • Successfully litigating ANDA cases on behalf of branded pharmaceuticals
  • Obtaining patents for therapeutic agents and methods currently in clinical trials, including tumor-specific agents such as oncolytics viruses and humanized antibodies and methods for treating strokes
  • Patenting groundbreaking tissue engineering patents on breakthroughs that show promise in treating spinal cord injuries
  • Obtaining the first patent on a genetically engineered animal
  • Gaining FDA approvals for small molecule drugs and biologics, including gene and cell therapies, antibiotics, immunologics, and anti-anxiety medications
  • Conducting intellectual property due diligence on thousands of licensing agreements for the merger of two large pharmaceuticals companies in just a few months’ time

Featured Video
A Conversation with Life Science Litigator Jonathan Singer

Featured Video
Principal, Gwilym Attwell Discusses Life Science Intellectual Property

Featured Experience

Search Fish Team

Search by Letter
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
No matches
Life Sciences

Life Sciences Team

What's Trending in Life Sciences

Filter by
Event
April 24th, 2017
Consero 2017 IP Forum for Life Sciences
Consero 2017 IP Forum for Life Sciences
Sponsorship
News
March 31, 2017
A Big Year Is Expected in Life Sciences Patent Litigation
Media Mention
Event
April 25th, 2017
Fish to Sponsor & Speak at C5 Pharma & Biotech Patent Litigation Conference
Speaking Engagement
Sponsorship
Q&A
March 22, 2017
Q&A with Chad Shear: A Big Year Is Expected in Life Sciences Patent Litigation
Q&A - Chad Shear
Author: W. Chad Shear
Event
April 25th, 2017 | 5:00 pm EDT
Delaware Bio 2017 Annual Awards Gala
Webinar: Patentability of Software After Alice
Sponsorship
Event
April 27th, 2017 | 7:30 am EDT
Joint Patent Practice (JPP) CLE: Information You Need On The Latest Patent Developments
Joint Patent Practice (JPP) CLE: Information You Need On The Latest Patent Developments
Speaking Engagement
Event
May 4th, 2017 | 6:00 pm EDT
2017 Franklin Institute Awards Ceremony & Dinner
2017 Franklin Institute Awards Ceremony & Dinner
Sponsorship
News
February 23, 2017
John Dragseth Quoted in Life Sciences Intellectual Property Review Article, "Life v Promega reaction: SCOTUS raises more questions"
Media Mention
News
February 3, 2017
Terry Mahn Quoted in Bloomberg BNA's "Generic Drugmaker Sues FDA to Get Its Exclusivity Back"
Media Mention
News
January 20, 2017
"Biosimilars: Looking Back and Looking Ahead" in Bloomberg Law
Articles
News
January 11, 2017
21st Century Cures Act: No Cure for an FDA Patent Bias
Articles
News
December 21, 2016
"US Solicitor Sides With Sandoz In Biosimilar Case" Law360 article
Media Mention
Articles
load more topics